Noting that the Republican and Democratic parties are in the midst of a major political realignment, former U.S. Health and Human Services Secretary Alex Azar II 88 said in a speech at 窪做惇蹋厙 last week that public distrust in governmental institutions has played into how Americans view health care policy and management.
While such distrust existed before the global disruption of COVID-19, COVID just hyperaccelerated that, Azar said in the Feb. 6 talk organized by the .
Azar clerked for Supreme Court Justice Antonin Scalia, served as general counsel to the secretary of health and human services from 2005 to 2007, was president of Lilly USA, LLC, the largest division of the pharmaceutical Eli Lilly and Company, and was named HHS secretary by President Donald Trump in 2018, in which capacity he served from 2019 to 2021.
You normally would think, Republicans are pro-pharma. Not so much anymore. Thats Big Pharma, big is bad. Leaders arent trusted very much. And that comes into health care, Azar said in a discussion co-sponsored by the and and moderated by Carrie Colla 01, adjunct professor in the Department of Economics, and , clinical professor of Business Administration at .
Because the problems besetting U.S. health care policy and administration are so complex, Azar said, thats why you see so much happen at the regulatory administrative state level instead of Congress doing its job and legislating in these areas because they just cant. They know they cant get their act together because of all these tribal, cross-cutting cleavages on issues.
About 85 people attended the speech in Filene Auditorium on a snowy night, and .
As an economics and government major at 窪做惇蹋厙, Azar credited his training for shaping the trajectory of his career. Literally, my career has been built on my 窪做惇蹋厙 microeconomics understanding applied against public policy, and trying to bring those insights into public policy. Everything I do in health care is about how can I take a system that right now does not function according to market forces and introduce more market forces into it.
Numerous people have asked Azar, he said, what to expect from Trump in his second term on health care.
If I had to describe President Trumps thinking or agenda on health care, it would be choice, competition and populism. Give patients choice, not mandates, said Azar, who was the architect in Trumps first term of Operation Warp Speed, which developed, manufactured and distributed the first COVID-19 vaccine.
One of the questions for the health care industry is how to handle the enormous price tag for patient care. How do government and the medical sector work together to deliver better, more efficient care?
The fee-for-service, health insurance model has its origins in the New Deal, Azar said. As it stands now, he added, our system is built to pay for (the cholesterol-lowering drug) Lipitor, its built to pay for pills. Its not built to pay for life-altering curative therapies that cost a million dollars. So we have to figure out new financing mechanisms. Thats an economic problem.
Asked what advice he might give, if asked, to Robert F. Kennedy, Jr., Trumps nominee for HHS secretary, Azar said he would first look to collaborate with civil servants.
Yes, there are issues with the administrative state, and yes, there are issues with too many people and sometimes people who dont align to whoevers electeds vision. But there are some quite good career people there. You cant get things done without working through and with those folks. I found most of the career people that I worked with to be very honorable and very understanding of our constitutional system of government, Azar said.
The second would be to emphasize preventive, or what Azar called value-based care, such as participating in telehealth, deciding on a home visit, sending a home health aide, sending meals to a house-bound patient, or installing a ramp or air conditioning, Azar said.
The reality, he added, is that American health care doesnt, as a rule, do these things. And its so pennywise, pound-foolish. We can save 5, 10 or 15%just from simple interventions like that.
Finally, Azar observed, even as the American model of health care seems unsustainable, the potential for breakthrough treatments for disease has never been greater. Were at a genuine golden age of medicine and biopharmaceuticals, he said.
I have been with a 19-year-old man who had sickle cell anemia, who went into a childrens hospital and 30 days later walked out after a gene cell transplant with no sickles in his blood. So he went from a shortened life, a life of pain and agony, to a hopefully lifelong cure of a disease, Azar said.
When scientists test drugs now, Azar said, the question is less, will this drug work as promised, but will there be off-target safety or efficacy effects that we couldnt have predicted in advance?
The potential for gene therapies has revolutionized health care. And my hope is that we will not kill this golden goose, because government and health care industries cant devise innovative ways to pay for such therapies, Azar said.
